Adarx Pharmaceuticals, Inc.

This early-stage study tests a new drug, ADX-038, first in healthy volunteers to check safety and dosing, then in people with PNH who still have anemia despite current treatment. The goal is to see if the drug is safe and how it works in the body. About 50 participants will take …

This study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys. The goal is to see if the drug is safe and can help control the disease. Some participants will get ADX-038 alone, and others will get it with a…

This study tests an experimental drug called ADX-324 in 90 adults with hereditary angioedema (HAE) types 1 or 2. The drug uses a technology called siRNA to lower a protein involved in swelling attacks. Participants receive either the drug or a placebo to see if it safely reduces …

This study is for people with hereditary angioedema (HAE) who have already completed a prior phase 3 trial of ADX-324. It aims to see how safe and effective the drug is over a longer period, and whether it can reduce the number of swelling attacks. About 90 adults will receive ad…

This study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug…

This study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system, such as IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have active kidney disease and be on…

This study is the first time ADX-626 is being tested in humans. It aims to check the drug's safety and how the body handles it in 44 healthy adults aged 18 to 45. Participants will receive either the drug or a placebo. This study does not aim to treat any disease.